Associated Papers
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
Detection of oncogenic and clinically actionable mutations in cancer genomes critically depends on variant calling tools.
Garcia-Prieto CA et al.
Bioinformatics (oxford, England), 2022
Ultrasensitive analysis of genetic instability related to chemical exposure.
Domoradzki T et al.
Journal of Applied Genetics, 2022
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Lee JH et al.
Cancer Medicine, 2021
Therapeutic management of neuro-oncologic patients - potential relevance of CSF liquid biopsy.
von Baumgarten L et al.
Theranostics, 2020
Clinical mutational profiling of 1006 lung cancers by next generation sequencing.
Illei PB et al.
Oncotarget, 2017
Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan.
Hsu KH et al.
Plos One, 2015
Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
Kaneda T et al.
Lung Cancer (amsterdam, Netherlands), 2014
Frequency of and variables associated with the EGFR mutation and its subtypes.
Tanaka T et al.
International Journal of Cancer, 2010
Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer.
Chen Z et al.
Plos One, 2009
Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients.
Reinmuth N et al.
Lung Cancer (amsterdam, Netherlands), 2008
Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer (amsterdam, Netherlands), 2008
Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.
Tsao AS et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2006
EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.
Tang X et al.
Cancer Research, 2005
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
Shigematsu H et al.
Journal of the National Cancer Institute, 2005